M1 Kliniken AG (MKLNF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
M1 Kliniken AG (MKLNF) trades at $11.73 with AI Score 42/100 (Grade C). M1 Kliniken AG operates medical centers specializing in aesthetic and plastic surgery across Europe and Australia. Market cap: $214.81M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for MKLNF: MKLNF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MKLNF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MKLNF: the 1 perspectives are evenly split.
How is this calculated? →M1 Kliniken AG (MKLNF) Healthcare & Pipeline Overview
M1 Kliniken AG, a European and Australian operator of aesthetic and plastic surgery clinics, differentiates itself through its integrated business model encompassing both medical services and the development/distribution of related pharmaceutical products, positioning it within the growing global aesthetic medicine market.
What Is the Investment Thesis for MKLNF?
M1 Kliniken AG presents an investment case centered on its integrated business model and expansion within the aesthetic medicine market. With a P/E ratio of 14.9 and a dividend yield of 3.29%, the company demonstrates potential value. A key growth catalyst is the increasing demand for aesthetic procedures globally. However, investors may want to evaluate the company's relatively low gross margin of 12.0% and the competitive landscape. The company's beta of 1.14 suggests a slightly higher volatility compared to the market. Further analysis should focus on the company's ability to maintain profitability and expand its market share in a competitive environment.
Based on FMP financials and quantitative analysis
MKLNF Key Highlights
- Market capitalization of $214.81M indicates its size within the medical care facilities industry.
- P/E ratio of 14.9 suggests a potentially reasonable valuation compared to its earnings.
- Dividend yield of 3.29% offers an income component for investors.
- Profit margin of 5.0% reflects the company's profitability after all expenses.
- Gross margin of 12.0% indicates the percentage of revenue exceeding the cost of goods sold.
Who Are MKLNF's Competitors?
MKLNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AONC American Oncology Network, Inc. | $10.00 | +0.00% | $292.48M | 50 |
| BRSYF BrainsWay Ltd. | $13.55 | -19.54% | $543.75M | 62 |
| GNFTF Genfit S.A. | $10.75 | +0.00% | $538.53M | 73 |
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| SLHGP Skylight Health Group Inc. | $12.00 | -5.88% | 61 | |
| NWKHY Netcare Limited | $7.17 | +0.00% | $843.64M | 50 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MKLNF's Key Strengths?
- Established presence in multiple European countries and Australia.
- Integrated business model with both medical services and product development.
- Recognized brand in the aesthetic medicine market.
- Diversified revenue streams from medical procedures and product sales.
What Are MKLNF's Weaknesses?
- Relatively low gross margin compared to industry peers.
- Dependence on consumer spending and discretionary income.
- Exposure to regulatory changes and healthcare policies.
- Limited information availability due to OTC listing.
What Could Drive MKLNF Stock Higher?
- Expansion of M1 Med Beauty centers into new locations.
- Development and launch of new aesthetic medicine products under the M1 Select brand.
- Potential acquisitions or partnerships with other healthcare companies.
- Increasing demand for aesthetic procedures in key markets.
- Growth of medical tourism and international patient base.
What Are the Key Risks for MKLNF?
- Economic downturns and reduced consumer spending on discretionary procedures.
- Increased competition from other aesthetic medicine providers.
- Changes in healthcare regulations and reimbursement policies.
- Negative publicity or adverse events affecting the company's reputation.
- Limited liquidity and price volatility due to OTC listing.
What Are the Growth Opportunities for MKLNF?
- Expansion into New Geographic Markets: M1 Kliniken AG has the opportunity to expand its presence into new geographic markets, particularly in regions with growing demand for aesthetic procedures. This expansion could involve establishing new clinics or partnering with existing healthcare providers. The global aesthetic medicine market is projected to reach $147.94 billion by 2030, presenting a substantial opportunity for growth. Timeline: Expansion efforts could begin within the next 1-2 years.
- Development of New Products and Services: Investing in the development of new and innovative products and services within the aesthetic medicine and cosmetic dermatology fields can drive growth. This could include new treatments, technologies, or product lines that cater to evolving consumer needs. The market for cosmetic dermatology is experiencing continuous innovation, with new products and services being introduced regularly. Timeline: Ongoing, with new product launches expected annually.
- Increased Focus on Medical Tourism: M1 Kliniken AG can capitalize on the growing trend of medical tourism by attracting patients from other countries seeking affordable and high-quality aesthetic procedures. This could involve marketing its services to international patients and establishing partnerships with travel agencies and tourism organizations. The global medical tourism market is expected to reach $237.7 billion by 2030. Timeline: Can be implemented within the next year.
- Strategic Acquisitions and Partnerships: Pursuing strategic acquisitions and partnerships with other companies in the healthcare sector can expand M1 Kliniken AG's capabilities and market reach. This could involve acquiring smaller clinics or partnering with pharmaceutical companies to develop and market new products. The healthcare industry is characterized by ongoing consolidation and collaboration. Timeline: Ongoing, with potential acquisitions and partnerships occurring periodically.
- Enhancement of Digital Marketing and Online Presence: Strengthening its digital marketing efforts and online presence can help M1 Kliniken AG attract more patients and increase brand awareness. This could involve investing in search engine optimization, social media marketing, and online advertising. The majority of consumers now research healthcare services online before making a decision. Timeline: Ongoing, with continuous improvement of digital marketing strategies.
What Opportunities Does MKLNF Have?
- Expansion into new geographic markets with high demand for aesthetic procedures.
- Development of new and innovative products and services.
- Increased focus on medical tourism.
- Strategic acquisitions and partnerships to expand capabilities.
What Threats Does MKLNF Face?
- Intense competition from other medical care providers and pharmaceutical companies.
- Economic downturns and reduced consumer spending.
- Negative publicity or adverse events affecting the company's reputation.
- Changes in healthcare regulations and reimbursement policies.
What Are MKLNF's Competitive Advantages?
- Established network of medical centers across multiple countries.
- Integrated business model encompassing both medical services and product development/distribution.
- Brand recognition and reputation within the aesthetic medicine market.
- Proprietary products and technologies developed and marketed under the M1 Select brand.
What Does MKLNF Do?
Founded in 2007 and based in Berlin, Germany, M1 Kliniken AG has established itself as a provider of aesthetic and plastic surgery services. Operating in two segments, Beauty and Trade, the company's Beauty segment focuses on its network of outpatient specialist centers and specialized surgical clinic centers operating under the M1 Med Beauty brand, totaling 46 specialist centers. These centers offer a range of aesthetic and plastic surgery procedures. The Trade segment develops and markets pharmaceutical, medical, and medical technology products for aesthetic medicine and cosmetic dermatology under the M1 Select brand. It also trades in pharmaceutical, biosimilars, and other medical products and devices in areas such as oncology, HIV, rheumatism, neurology, cardiovascular diseases, and narcotics. M1 Kliniken AG extends its business to the acquisition, management, and sale of real estate, primarily within the healthcare sector. The company's geographic footprint spans Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, and Australia. M1 Kliniken AG operates as a subsidiary of MPH Health Care AG.
What Products and Services Does MKLNF Offer?
- Operates medical centers for aesthetic and plastic surgery.
- Develops and markets pharmaceutical, medical, and medical technology products.
- Trades in pharmaceutical, biosimilars, and other medical products.
- Offers products to doctors, pharmacies, and wholesalers under the M1 Select brand.
- Manages a network of outpatient specialist centers.
- Operates a specialized surgical clinic center.
- Engages in the acquisition, management, and sale of real estate in the healthcare sector.
How Does MKLNF Make Money?
- Generates revenue from aesthetic and plastic surgery procedures performed at its medical centers.
- Generates revenue from the sale of pharmaceutical, medical, and medical technology products.
- Generates revenue from trading in pharmaceutical, biosimilars, and other medical products.
What Industry Does MKLNF Operate In?
M1 Kliniken AG operates within the medical care facilities industry, which is experiencing growth driven by increasing demand for aesthetic and plastic surgery. The global aesthetic medicine market is projected to reach significant growth by 2030. The competitive landscape includes other medical care providers and pharmaceutical companies. M1 Kliniken AG differentiates itself through its integrated model, combining medical services with the development and distribution of related products. The company's success depends on its ability to adapt to changing consumer preferences and regulatory requirements.
Who Are MKLNF's Key Customers?
- Individuals seeking aesthetic and plastic surgery procedures.
- Doctors, pharmacies, and wholesalers who purchase the company's products.
- Patients requiring pharmaceutical and medical products in areas such as oncology, HIV, rheumatism, neurology, and cardiovascular diseases.
M1 Kliniken AG (MKLNF) Valuation Context
Valued at $214.81M, MKLNF is classified as a micro-cap stock. Relative to its peer group, MKLNF's quantitative score of 42/100 is below the peer average of 63/100.
ROE 19%Key Financial Metrics
Return on equity for M1 Kliniken AG stands at 18.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 11.7%, showing how much profit it generates from its asset base. MKLNF trades at a trailing price-to-earnings ratio of 14.91, below the Healthcare sector average of ~23x. Its free cash flow yield is 9.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.82 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.4%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 8/9Financial Health
M1 Kliniken AG's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 8.56 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project M1 Kliniken AG revenue of about $370.9M for fiscal 2026, with EPS near $1.09.
MKLNF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Market sentiment data being refreshed
- Community discussions being analyzed
Bear Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Risk factors being evaluated
- Market concerns being processed
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MKLNF Latest News
No recent news available for MKLNF.
MKLNF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MKLNF.
Price Targets
Wall Street price target analysis for MKLNF.
MKLNF MoonshotScore
What does this score mean?
The MoonshotScore rates MKLNF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Kilian Brenske
Unknown
Information on Kilian Brenske's background is not available in the provided context. Further research would be needed to detail his career history, education, and previous roles.
Track Record: Information on Kilian Brenske's track record is not available in the provided context. Further research would be needed to assess his achievements and strategic decisions as CEO.
MKLNF OTC Market Information
The OTC Other tier, where M1 Kliniken AG trades, represents the lowest tier of the OTC market. Companies in this tier may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. This often indicates limited regulatory oversight and potentially higher risks compared to companies listed on major exchanges like the NYSE or NASDAQ. Investors should be aware that companies on the OTC Other tier may have limited information available and may not be subject to the same level of scrutiny as exchange-listed companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC listing.
- Lower liquidity and potential price volatility.
- Higher risk of fraud or manipulation compared to exchange-listed stocks.
- Limited regulatory oversight and investor protection.
- Potential difficulties in obtaining accurate and timely information.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Review the company's shareholder structure and ownership.
- Consult with a qualified financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Established business operations in multiple countries.
- Audited financial statements (if available).
- Presence of a recognized brand in the aesthetic medicine market.
- Membership in industry associations or trade groups.
- Positive customer reviews and testimonials.
Common Questions About MKLNF (Healthcare)
What does M1 Kliniken AG do?
M1 Kliniken AG operates medical centers specializing in aesthetic and plastic surgery across Europe and Australia. The company also develops, markets, and trades pharmaceutical, medical, and medical technology products for aesthetic medicine and cosmetic dermatology. Its business model combines medical services with the development and distribution of related products, targeting individuals seeking aesthetic enhancements and healthcare professionals in the aesthetic medicine field. The company operates under the M1 Med Beauty brand for its clinics and the M1 Select brand for its products.
What are the main risks for MKLNF?
M1 Kliniken AG faces several risks, including economic downturns that could reduce consumer spending on aesthetic procedures. Increased competition from other aesthetic medicine providers could also impact market share. Changes in healthcare regulations and reimbursement policies could affect profitability. Negative publicity or adverse events could damage the company's reputation. Additionally, the company's OTC listing presents risks related to limited liquidity, price volatility, and information availability.
What are the key factors to evaluate for MKLNF?
M1 Kliniken AG (MKLNF) holds an AI score of 42/100 (low). P/E: 14.9x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does MKLNF data refresh on this page?
MKLNF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MKLNF's recent stock price performance?
M1 Kliniken AG (MKLNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence in multiple European countries and Australia. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MKLNF overvalued or undervalued right now?
M1 Kliniken AG (MKLNF) trades at 14.9x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying MKLNF?
Before investing in M1 Kliniken AG (MKLNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding MKLNF to a portfolio?
Key strength of M1 Kliniken AG (MKLNF): Established presence in multiple European countries and Australia. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for OTC-listed companies.
- Analyst consensus may not be readily available.